期刊文献+

慢性乙肝肝纤维化不同分期TNF-α、NO和内毒素水平变化 被引量:4

Changes of TNF-α、NO and Endotoxin in Different Stages of Liver Fibrosis
下载PDF
导出
摘要 探讨慢性乙肝肝纤维化不同分期TNF-α、NO和内毒素水平变化及其对肝纤维化的影响。经肝穿刺活检证实慢性乙肝肝纤维化患者100例,其中按S期又分为S120例、S225例、S330例、S425例;或按G期又分为G120例、G230例、G325例、G425例。对照组为20名健康人。所有患者肝穿刺的同时,取血清测NO、TNFα-和内毒素。结果表明:TNF-α随肝炎程度及肝纤维化程度加重而升高,相关r分别为0.623(P<0.05)、0.649(P<0.01),NO为0.328(P>0.05),内毒素在肝纤维化阶段尚无明显增高。结论:TNFα-在慢性乙肝发展至肝硬化过程中,始终起着重要作用;NO早期未参与肝硬化的形成与发展。 To discuss the alteration of cytokines in different stages of liver fibrosis and their influence on the formation and development of liver fibrosis. 100 patients with liver fibrosis had been demonstrated by liver biopsy and were classified under two types: as S1 20 cases ,S2 25 cases ,S3 30 cases and S4 25 cases;or G1 20 cases, G2 30 cases, G3 25 cases and G4 25 cases. 20 healthy subjects were in control group. At the same time of liver biopsy, serum was to be measured for NO, TNF-a, endotoxin. Results showed that TNF-a in hepatitis and liver fibrosis ,correlated with stages, r=0. 623(P〈0.05), 0. 649 (P〈0.01) respectively, NO was not correlated r: 0. 328(P〉0.05), endotoxin in liver fibrosis stage had not increased obviously. Endotoxin does not participate in chronic lesion of liver in early stage of the disease. In conclusion TNF-c~ plays an important into liver cirrhosis; NO has nothing to do with liver role all along in development of chronic hepatitis hardening in formation and development of liver cirrhosis in early stage.
出处 《标记免疫分析与临床》 CAS 2006年第3期131-132,共2页 Labeled Immunoassays and Clinical Medicine
关键词 肝纤维化 肝硬化 一氧化氮 肿瘤坏死因子 内毒素 Liver fibrosis Liver cirrhosis Nitrogen oxide Tumor nocrosis factor Endotoxin
  • 相关文献

参考文献5

二级参考文献11

  • 1Ya. Sh. Shvarts,A. A. Zubakhin,M. I. Dushkin. Suppression of hemopoiesis during CCl4-induced hepatic fibrosis: Role of systemic endotoxemia[J] 2000,Bulletin of Experimental Biology and Medicine(2):759~762
  • 2GoeddelDV.Signaltransductionbytumornecrosisfactor:theparkerB .Francislectureship[].Chest.1999
  • 3Neurath MF,Fuss I,Pasparakis M,et al.Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice[].European Journal of Immunology.1997
  • 4Targan SR,Hanauer SB,van-Deventer SJ,et al.A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease[].The New England Journal of Medicine.1997
  • 5D’haens G,Van-Deventer S,Van-Hogezand R,et al.Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial[].Gastroenterology.1999
  • 6Rutgeerts P,D’Haens G,Targan S,et al.Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease[].Gastroenterology.1999
  • 7Papadakis KA,Targan SR.Tumor necrosis factor: biology and therapeutic inhibitors[].Gastroenterology.2000
  • 8Knight DM,Trinh H,Le J,et al.Construction and initial characterization of a mouse-human chimeric anti-TNF antibody[].Molecular Immunology.1993
  • 9Kugathasan S,Werlin SL,Martinez A,et al.Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease[].The American journal of Gastroenterology.2000
  • 10Hyams JS,Markowitz J,Wyllie R.Use of infliximab in the treatment of Crohn’s disease in children and adolescents[].The Journal of Pediatrics.2000

共引文献101

同被引文献48

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部